Thermogenesis Holdings, INC
Market Movers (8-K)
OTC.Pink
ThermoGenesis Holdings, Inc. has announced the immediate closure of its Indian subsidiary, TotipotentRx Cell Therapy Private Limited, effective December 31, 2024.
OTC.Pink
ThermoGenesis Holdings has replaced its independent auditor, Marcum LLP, with Simon & Edward LLP, effective August 1, 2024.
Worse than expected
OTC.Pink
ThermoGenesis Holdings, Inc. announces the immediate resignation of its Chief Financial Officer, Jeffery Cauble, effective June 15, 2024.
Worse than expected
OTC.Pink
ThermoGenesis Holdings has lost control of its subsidiary, ThermoGenesis Corp, after defaulting on a loan agreement with Boyalife Group (USA), Inc.
Worse than expected
OTC.Pink
ThermoGenesis Holdings has received a default notice from Boyalife Group due to a missed interest payment, potentially leading to the seizure of its subsidiary, ThermoGenesis Corp.
Worse than expected
OTC.Pink
ThermoGenesis Holdings converted $3 million of debt into equity, issuing 7,894,737 shares of common stock.
Quarterly Earnings (10-Q)
OTC.Pink
ThermoGenesis Holdings saw a revenue increase in Q1 2024, but continues to face substantial financial challenges and going concern doubts.
Capital raise
Better than expected
Annual Reports (10-K)
OTC.Pink
ThermoGenesis Holdings, Inc. released its annual 10-K report, outlining its financial performance, strategic initiatives, and risk factors for the fiscal year ended December 31, 2023.
Capital raise
Worse than expected